- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07454148
Étude prospective CART-BP pour le contrôle de l'hypertension
Efficacité et Sécurité de la Gestion de la Pression Artérielle Guidée par CART BP chez les Patients Coréens Souffrant d'Hypertension Non Contrôlée : Une Étude Prospective Non Randomisée
This prospective, open-label, non-randomized study evaluates the effectiveness and safety of a CART BP pro(a brand name of cuffless ambulatory blood pressure monitoring device)-guided blood pressure management strategy in Korean patients with uncontrolled hypertension. Participants are allocated to either a CART BP pro-guided management group or a usual care group based on clinical decision and participant preference. The primary efficacy endpoint is 24-hour mean ambulatory systolic blood pressure at 24 weeks; safety outcomes including treatment-emergent adverse events (TEAEs) are also assessed.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Hypertension remains suboptimally controlled despite combination pharmacotherapy, and office blood pressure measurements may not adequately reflect true ambulatory blood pressure burden and nocturnal patterns. CART BP pro is a wearable, cuffless photoplethysmography-based continuous blood pressure monitoring device. This study investigates whether a CART BP pro-guided antihypertensive titration strategy improves 24-hour ambulatory blood pressure control compared with usual care in real-world outpatient settings. Participants receive standard antihypertensive medications (e.g., angiotensin receptor blocker [ARB], calcium channel blocker [CCB], thiazide diuretic) per guideline-based care. In the CART BP pro-guided group, medication adjustments are informed by CART BP pro-derived 24-hour blood pressure data. The planned follow-up was 24 weeks. Prospective data collection under this non-randomized study protocol has ended. The optional extension to 48 weeks was not undertaken. A separate randomized controlled trial, CARTBP-HTN-P2-2025 (NCT07465549), is ongoing to evaluate CART BP pro-guided blood pressure management under a randomized design. Any future analyses of routinely collected clinical data would be retrospective and subject to applicable institutional review board and consent requirements.
The total actual enrollment was 286 participants. The initial publication (PMID: 42846709) reported a subcohort of 246 participants (67 in the CART BP arm and 179 in the usual-care arm) using data available as of April 6, 2026. Eight participants were lost to follow-up. Of the remaining 238 participants, 162 had valid follow-up ambulatory blood pressure recordings and were included in the primary analysis (38 in the CART BP arm and 124 in the usual-care arm); 76 did not have a valid recording. These publication-specific populations are distinct from the total enrollment of the study.
The registered primary outcome is 24-hour mean ambulatory systolic blood pressure at 24 weeks. The publication described the outcome assessment as the 6-month visit and reported median recording times of 181 days after the index visit in the CART BP arm and 188 days in the usual-care arm. Both arms were scheduled to undergo CART BP pro recording for the outcome assessment. Because ambulatory blood pressure was not systematically measured at baseline, the published primary endpoint was the follow-up blood pressure level, not within-participant change from baseline.
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
Choose One...
-
Seoul, Choose One..., Corée du Sud, 02841
- Korea University Anam Hospital
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Age >= 19 years
- Office systolic blood pressure(BP) >= 140 mmHg or diastolic BP >= 90 mmHg
- Able and willing to provide written informed consent and comply with follow-up visits
Exclusion Criteria:
- History of intolerance to olmesartan, amlodipine, or hydrochlorothiazide
- Suspected secondary hypertension
- Atrial fibrillation
- Pregnancy or lactation
- Other serious medical condition that may interfere with study participation
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Non randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: CART BP pro-guided management
Participants undergo 24-hour continuous blood pressure monitoring with CART BP pro. Antihypertensive medications are adjusted based on ambulatory blood pressure data. |
Wearable cuffless continuous blood pressure monitoring device. |
|
Comparateur actif: Usual care
Participants receive antihypertensive medication adjustments based on office blood pressure measurements according to standard clinical practice. |
Standard hypertension management based on office blood pressure. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
24-hour mean systolic blood pressure
Délai: 24 weeks
|
Between-group difference in 24-hour mean ambulatory systolic blood pressure measured using the CART BP Pro device at 24 weeks. |
24 weeks
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Incidence of treatment-emergent adverse events (TEAE)
Délai: 24 weeks
|
Proportion of participants experiencing TEAEs during the 24-week study period. |
24 weeks
|
|
24-hour blood pressure load
Délai: 24 weeks
|
Percentage of valid ambulatory BP readings exceeding prespecified thresholds over 24 hours. |
24 weeks
|
|
Office blood pressure change
Délai: 24 weeks
|
Change in office systolic and diastolic blood pressure from baseline to 24 weeks. |
24 weeks
|
|
Target blood pressure achievement rate
Délai: 24 weeks
|
Proportion of participants achieving prespecified ambulatory BP targets. |
24 weeks
|
Collaborateurs et enquêteurs
Parrainer
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- CARTBP-HTN-P1-2025
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
De-identified individual participant data collected in this study are not currently planned to be shared with external researchers. Data sharing may be considered in the future subject to institutional review board approval and institutional data governance policies.
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .